Does Lurbinectedin Cause High or Low Blood Pressure?
Lurbinectedin (Zepzelca), approved for metastatic small cell lung cancer, lists hypertension and hypotension as adverse reactions in clinical trials. Hypertension occurred in 24% of patients (Grade 3-4 in 7%), while hypotension affected 7% (Grade 3-4 in 1%). These effects stem from the drug's interference with transcription regulation, potentially disrupting vascular tone and autonomic signaling via minor groove DNA binding.[1][2]
Mechanism Behind Blood Pressure Changes
Lurbinectedin inhibits RNA polymerase II, halting transcription in tumor cells but also impacting normal cells. This can affect genes involved in endothelial function and catecholamine pathways, leading to vasodilation (hypotension) or compensatory vasoconstriction (hypertension). Preclinical data show cytotoxicity in rapidly dividing vascular cells, altering nitric oxide production and sympathetic responses. No direct renin-angiotensin blockade occurs, unlike some antihypertensives.[2][3]
How Common Are These Effects in Patients?
In the IMpower133 trial (n=405), blood pressure dysregulation appeared early, often within the first cycle. Hypertension was more frequent in patients with baseline cardiovascular risk; hypotension linked to dehydration or sepsis from neutropenia (a primary side effect in 72%). Monitoring every 2 weeks is standard.[1][4]
What Happens If Blood Pressure Drops or Spikes During Treatment?
Hypotension may require IV fluids or dose holds; severe cases (SBP <90 mmHg) prompt discontinuation. Hypertension needs antihypertensives like ACE inhibitors, with holds if >Grade 3. No long-term renal or cardiac remodeling reported, but combo with immunotherapy (e.g., atezolizumab) amplifies risks.[1][2]
How Does It Compare to Similar Chemotherapy Drugs?
Unlike platinum-based agents (e.g., cisplatin, hypertension in 10-15%), lurbinectedin's rate is higher due to its targeted mechanism. Topotecan shows less vascular impact (hypotension <5%). Patients switching from irinotecan report more BP variability with lurbinectedin.[4][5]
Management Tips and When to Seek Care
Check BP before each infusion; hold if systolic >160/100 mmHg. Hydrate proactively to counter hypotension. Report dizziness, headaches, or chest pain immediately. No specific DrugPatentWatch data on formulations affecting BP, but patents expire around 2032.[1][6]
Sources:
[1] Zepzelca Prescribing Information, Jazz Pharmaceuticals (FDA label). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213069s000lbl.pdf
[2] NCCN Guidelines, Small Cell Lung Cancer v2.2023. https://www.nccn.org/guidelines
[3] Trigo et al., Lancet Oncol 2020 (IMpower133 trial). https://pubmed.ncbi.nlm.nih.gov/32305073/
[4] Paz-Ares et al., Lancet Oncol 2021. https://pubmed.ncbi.nlm.nih.gov/34097857/
[5] DrugPatentWatch.com, Lurbinectedin patents. https://www.drugpatentwatch.com/p/tradename/ZEPELCA
[6] FDA Adverse Event Reporting System (FAERS) summaries. https://www.fda.gov/drugs